Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications

Bryce J B Nelson; John Wilson; Jan D Andersson; Frank Wuest

doi:10.3390/ph16111622

Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications

Pharmaceuticals (Basel). 2023 Nov 17;16(11):1622. doi: 10.3390/ph16111622.

Authors

Bryce J B Nelson¹, John Wilson¹, Jan D Andersson^{1

2}, Frank Wuest^{1

3}

Affiliations

¹ Department of Oncology, University of Alberta, 11560 University Ave., Edmonton, AB T6G 1Z2, Canada.
² Edmonton Radiopharmaceutical Center, Alberta Health Services, 11560 University Ave., Edmonton, AB T6G 1Z2, Canada.
³ Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB T6G 2E1, Canada.

Abstract

This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: ¹³³La, ¹³²La, ¹³⁴Ce/¹³⁴La, and ²²⁶Ac for ²²⁵Ac TAT; ²⁰³Pb for ²¹²Pb TAT; ¹³¹Ba for ²²³Ra and ²²⁴Ra TAT; ¹²³I, ¹²⁴I, ¹³¹I and ²⁰⁹At for ²¹¹At TAT; ¹³⁴Ce/¹³⁴La for ²²⁷Th TAT; and ¹⁵⁵Tb and ¹⁵²Tb for ¹⁴⁹Tb TAT.

Keywords: PET imaging; SPECT imaging; actinium-225; alpha particle therapy; lanthanum-133; lead-203; lead-212; targeted alpha therapy; targeted radionuclide therapy; theranostics.

Publication types

Review

Grants and funding

The authors would like to thank the Dianne and Irving Kipnes Foundation for supporting this work.